# Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

> **NCT03211247** · PHASE3 · COMPLETED · sponsor: **DBV Technologies** · enrollment: 414 (actual)

## Conditions studied

- Peanut Allergy

## Interventions

- **BIOLOGICAL:** Part A Viaskin Peanut 250 mcg
- **BIOLOGICAL:** Part A Viaskin Peanut 100 mcg
- **BIOLOGICAL:** Part A Placebo
- **BIOLOGICAL:** Part B Viaskin Peanut 250 mcg
- **BIOLOGICAL:** Part B Placebo

## Key facts

- **NCT ID:** NCT03211247
- **Lead sponsor:** DBV Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-31
- **Primary completion:** 2019-08-20
- **Final completion:** 2022-04-27
- **Target enrollment:** 414 (ACTUAL)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03211247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03211247, "Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03211247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*